Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

• Sambasiva P. Rao ,

  * E-mail: Sambasiva.rao@genzyme.com

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Jose Sancho,

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Juanita Campos-Rivera,

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Paula M. Boutin,

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Peter B. Severy,

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Timothy Weeden,

  Affiliation Immune Mediated Disease Biology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Srinivas Shankara,

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Bruce L. Roberts,

  Affiliations Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America, Immune Mediated Disease Biology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯
• Johanne M. Kaplan

  Affiliation Neuroimmunology Research, Genzyme, A Sanofi Company, Framingham, Massachusetts, United States of America

  ⨯